ACK1/TNK2激酶:分子机制和新兴的癌症治疗方法
Dhivya Sridaran1, Nupam P Mahajan2
1Division of Urologic Surgery, Department of Surgery, Washington University at St. Louis, St. Louis, MO 63110, USA.
Trends in pharmacological sciences
|December 25, 2024
概括
激活的CDC42-关联酶1 (ACK1) 是一种驱动癌症进展和表观遗传调节的可酶. 新的研究突出了其免疫调节作用和有希望的小分子抑制剂,正在迈向临床试验.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 激活的CDC42-关联激酶1 (ACK1),由TNK2基因编码,是一种细胞质非受体激素激酶.
- 异常的ACK1激活与癌症严重程度的增加和多种恶性瘤的进展有关.
- ACK1作为表观遗传调节剂,有助于瘤的发展.
研究的目的:
- 总结了解ACK1调节和信号通路的最新进展.
- 阐明ACK1的免疫调节功能,特别是在T细胞激活中.
- 审查针对ACK1进行癌症治疗的小分子抑制剂的临床前数据.
主要方法:
- 关于ACK的最新研究的文献综述1.
- 对ACK1在表观遗传调节和癌症进展中的作用的研究分析.
- 对针对ACK1的小分子抑制剂的临床前数据的概述.
主要成果:
- 证实了ACK1通过表观遗传机制推动癌症进展的关键作用.
- ACK1影响T细胞激活,这表明它在癌症免疫力中起作用.
- 几种强大的ACK1向小分子抑制剂在临床前研究中显示出有前途.
结论:
- ACK1是一种具有治疗潜力的显著的可基因酶和表观遗传调节剂.
- 了解ACK1的信号传递和免疫调节作用对于开发有效的癌症治疗至关重要.
- 有前途的ACK1抑制剂正在进入临床试验,为癌症患者提供新的治疗途径.
相关概念视频
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K


